StemRIM Inc. announced that Shionogi & Co. Ltd. has notified that the first patient has been administered of the global late phase 2 clinical trial for Redasemtide targeting acute ischemic stroke in Japan. This clinical trial is a global late phase 2 clinical trial, planned to be conducted in 19 countries
worldwide, including Japan, the United States, and Europe. It aims to evaluate the effectiveness and safety of administering Redasemtide to 627 patients with acute ischemic stroke, aged 18 years and above, within 25 hours of symptom onset.